中华全科医师杂志
中華全科醫師雜誌
중화전과의사잡지
CHINESE JOURNAL OF GENERAL PRACTITIONERS
2014年
10期
832-834
,共3页
自身炎症性疾病%综合征
自身炎癥性疾病%綜閤徵
자신염증성질병%종합정
Autoinflammatory diseases%Syndrome
报告3例自身炎症性疾病.1例为19岁女性,出生后即出现周期性发热伴荨麻疹,特征性容貌,伴寡关节炎及中枢神经系统受累,发作期急性反应物质显著升高,诊断为慢性婴儿神经皮肤关节综合征,短期应用肿瘤坏死因子α受体拮抗剂有效.另2例均为男性,幼年发病,发作期急性反应物质显著升高.1例周期性发热伴荨麻疹样皮疹、关节痛、头痛,结合NLRP3基因突变,确诊为Muckle-Wells综合征.1例反复荨麻疹伴结膜炎、寡关节炎、肝脾大、IgD升高,临床诊断为甲羟戊酸激酶缺乏症.诊断自身炎症性疾病需结合临床表现和基因检测,生物制剂尤其是IL-1拮抗剂在该病应用前景广泛.
報告3例自身炎癥性疾病.1例為19歲女性,齣生後即齣現週期性髮熱伴蕁痳疹,特徵性容貌,伴寡關節炎及中樞神經繫統受纍,髮作期急性反應物質顯著升高,診斷為慢性嬰兒神經皮膚關節綜閤徵,短期應用腫瘤壞死因子α受體拮抗劑有效.另2例均為男性,幼年髮病,髮作期急性反應物質顯著升高.1例週期性髮熱伴蕁痳疹樣皮疹、關節痛、頭痛,結閤NLRP3基因突變,確診為Muckle-Wells綜閤徵.1例反複蕁痳疹伴結膜炎、寡關節炎、肝脾大、IgD升高,臨床診斷為甲羥戊痠激酶缺乏癥.診斷自身炎癥性疾病需結閤臨床錶現和基因檢測,生物製劑尤其是IL-1拮抗劑在該病應用前景廣汎.
보고3례자신염증성질병.1례위19세녀성,출생후즉출현주기성발열반담마진,특정성용모,반과관절염급중추신경계통수루,발작기급성반응물질현저승고,진단위만성영인신경피부관절종합정,단기응용종류배사인자α수체길항제유효.령2례균위남성,유년발병,발작기급성반응물질현저승고.1례주기성발열반담마진양피진、관절통、두통,결합NLRP3기인돌변,학진위Muckle-Wells종합정.1례반복담마진반결막염、과관절염、간비대、IgD승고,림상진단위갑간무산격매결핍증.진단자신염증성질병수결합림상표현화기인검측,생물제제우기시IL-1길항제재해병응용전경엄범.
Patient one was a 19-year-old woman of periodic fever with urticaria during the first week of life.And there were typical " facies",oligoarthritis and central nervous system involvement.She also exhibited a persistent elevation of acute phase reactants.The diagnosis of chronic infantile neurological cutaneous and articular syndrome was made.Short-term dosing of tumor necrosis factor-α receptor antagonist was administrated and was substituted by glucocorticoid and methotrexate.Another two males had an earlyonset of increased acute phase reactants during inflammation attacks.One of them had recurrent fever with urticaria-like rash,arthralgia and headache.Muckle-Wells syndrome was diagnosed on basis of NLRP3 gene mutation (c.92A > T).And another had recurrent urticaria-like rash with conjunctivitis,oligoarthritis,hepatosplenomegaly and increased serum IgD.The clinical diagnosis was mevalonate-kinase deficiency.Autoinflammatory diseases should be suspected by physicians and diagnosed with a combination of phenotype and genotype.Biological agents,especially interleukin-1 antagonist,have broad prospects in the therapy of autoinflammatory diseases.